Health Secretary Robert F. Kennedy Jr. told Joe Rogan the administration is eager to expand access, especially for veterans, but the legal and regulatory path remains unclear.
Robert F. Kennedy Jr. did on a wildly popular podcast what cabinet secretaries do not usually do in public: he made a sweeping promise before the bureaucracy had shown its full paperwork.
In a recent appearance on “The Joe Rogan Experience”, the Health and Human Services secretary said the administration is “very anxious” to create a rule that would expand psychedelic therapy in therapeutic settings, especially for troops and veterans, and said officials want to move “as quickly as possible.”
Those remarks matter because they add fresh force to an idea that has been gathering allies inside Washington for months: psychedelic therapy for PTSD, depression and related conditions has moved from fringe curiosity to active federal interest.
The enthusiasm is real. The access pathway is still foggy. No new national program for broad patient access has been announced, the Food and Drug Administration has not reversed its 2024 rejection of MDMA-assisted therapy for PTSD, and MDMA and psilocybin remain tightly restricted under federal drug law.
Kennedy’s phrasing on Rogan was revealing. He talked about clinical rules, therapeutic settings and strong guidelines. He also said the administration needs “baby steps” and a “very controlled setting,” warning against a “Wild West” rollout that could produce bad outcomes and instantly poison the politics.
That is a medical model, not a retail model. It is the language of supervised care, follow-up visits and federal guardrails, even if the details behind those guardrails remain unwritten in public.
The comments also were not an isolated flourish. In July, The Associated Press reported that Kennedy had told lawmakers he was working to make these therapies available within 12 months.
The same AP report said FDA Commissioner Marty Makary had made the evaluation of MDMA and other psychedelics a top priority, while Veterans Affairs Secretary Doug Collins signaled openness to the push. That does not amount to approval. It does signal that the center of gravity inside the administration has shifted from skepticism to active interest.
For cannabis readers, the rhythm is familiar. Federal culture can move faster than federal code. Washington can become more comfortable with taboo therapeutics long before the scheduling system, trial standards and agency review process catch up.
Psychedelic therapy now sits in a zone that cannabis communities know well: politically attractive, culturally ascendant and still fenced in by the machinery of federal law.
Federal research already has a foot in the door
The administration does not start from zero. In December 2024, the Department of Veterans Affairs announced funding for its first VA-backed psychedelic-assisted therapy study since the 1960s. The project is designed to examine MDMA-assisted therapy for veterans with PTSD and alcohol use disorder, with researchers affiliated with Brown and Yale.
Earlier VA statements also tied psychedelic research to rising pressure from veteran service organizations and noted that the 2024 National Defense Authorization Act authorized psychedelic study inside military populations.
The Defense Department has gone further than casual curiosity. Congress appropriated $10 million for Defense-wide psychedelic clinical trials, and a January 2026 Defense Health Agency report said the money is supporting two phase 2 MDMA-related PTSD studies: one through Walter Reed National Military Medical Center and the Henry M. Jackson Foundation, and another led by UT Health San Antonio with enrollment at San Antonio and Emory sites. Emory described its project as part of the Pentagon’s first financial commitment to clinical trials focused on modern psychedelics.
That distinction matters. Research is not access. A grant announcement is not an approval letter. The Defense report says participant enrollment in those funded trials had not yet begun as of January, and VA’s own PTSD resources still say MDMA is not approved for clinical use by the FDA and can be studied only in research settings. Federal involvement is real. Widespread psychedelic therapy for patients remains hypothetical.
Veterans have been one of the most effective pressure blocs in this debate, which helps explain Kennedy’s framing. AP reported that the nonprofit Veterans Exploring Treatment Solutions, or VETS, has helped more than 1,000 veterans travel abroad for ibogaine and other psychedelic treatments.
Kennedy echoed that moral and political argument on Rogan, saying service members should not have to leave the country to seek care they believe helped them. That message has emotional force, especially in a PTSD policy space where conventional treatments do not work for everyone.
The barrier is still the FDA and the Controlled Substances Act
The central problem for psychedelic therapy is that political urgency does not erase regulatory history. In August 2024, the FDA declined to approve Lykos Therapeutics’ application for midomafetamine, the FDA’s name for MDMA, as a PTSD treatment.
The agency’s complete response letter said the application did not provide substantial evidence of effectiveness or establish safety, cited unreported adverse events that raised concerns about the reliability of the safety data, and said the company had not shown that benefits were durable beyond the 18-week end-of-study assessments. AP reported the agency also requested another late-stage study.
The warning lights came on even earlier. In June 2024, an FDA advisory committee voted 10-1 against the overall benefits of MDMA for PTSD after raising concerns about flawed study data, questionable research conduct and risks that included heart problems, injury and abuse.
The FDA has continued to encourage psychedelic research, and its 2023 draft guidance still lays out how sponsors can study these drugs. None of that changes the core fact that psychedelic therapy still has to survive ordinary federal review, with all the unglamorous rules that phrase implies.
The legal status of the substances adds another drag factor. The DEA says Schedule I substances have no currently accepted medical use and a high potential for abuse, and its examples of Schedule I drugs include MDMA. The agency’s psilocybin materials likewise say the compound remains Schedule I. Kennedy can champion psychedelic therapy all he wants.
Any broad access plan still has to pass through the federal system that classifies the underlying drugs among the most restricted substances in American law.
The evidence is promising, and the argument is still contested
Supporters of psychedelic therapy are not arguing from vibes alone. The best-known evidence for MDMA-assisted therapy in PTSD comes from a 2021 phase 3 trial in Nature Medicine and a 2023 phase 3 trial in the same journal.
Those studies reported significant reductions in PTSD symptoms and functional impairment, and the 2023 paper described MDMA-assisted therapy as generally well tolerated while meeting its primary and secondary endpoints. In a field where many patients cycle through SSRIs, talk therapy and relapse, that kind of result is exactly how a once-taboo treatment starts to look medically serious.
Still, promising does not mean settled. A 2024 JAMA Psychiatry viewpoint argued that the psychotherapy component in MDMA-assisted psychotherapy has been critically overlooked in judging the validity of the trials. The Institute for Clinical and Economic Review concluded that the current publicly available evidence for MDMA-assisted psychotherapy was insufficient to compare it with trauma-focused psychotherapies.
FDA reviewers and outside critics have also worried about functional unblinding, which is a dry technical phrase for a simple problem: when patients and therapists can tell who got the drug, expectation can leak into the result. Psychedelic therapy may yet prove transformative. The case is not finished simply because the headlines were exciting.
That skepticism is not anti-patient. It is the part of the story that keeps patients from becoming casualties of a movement’s impatience. Yale researcher Philip Corlett told AP that bypassing rigorous clinical trials could set back the field and jeopardize patients.
Nora Volkow, the longtime head of the National Institute on Drug Abuse, told AP she is intrigued by psychedelics’ pharmacological properties while also warning that the field cannot afford to fall into hype. Those are not prohibitionist talking points. They are reminders that psychedelic therapy will only last as a credible medical project if the evidence can survive scrutiny from people who are paid to doubt it.
The administration is signaling speed without a public map
Kennedy’s Rogan appearance supplied urgency, sympathy and political intent. It did not supply a public roadmap. He did not explain whether the administration’s preferred route is a new FDA approval, expanded compassionate-access mechanisms, more federally backed trials, rescheduling, narrower veteran-focused pilots or some combination of all four.
The public materials currently available still point to research programs, draft guidance and agency review, not a ready-made national access channel for psychedelic therapy.
That leaves the story in a familiar American place: speed in the rhetoric, process in the fine print. The administration is clearly trying to tell veterans, clinicians and advocates that psychedelic therapy has friends in high office.
The law is still the law, the FDA file is still unresolved and the people who could benefit right now are still largely confined to trials, tightly controlled settings or expensive trips outside the United States. Kennedy may want the fast path. The country still has the long paperwork.
***
Trap Culture is the ultimate destination for cannabis enthusiasts who want to experience the best of Arizona’s cannabis culture. Whether you are looking for the hottest cannabis-friendly events, the latest news on cannabis legalization, trends in the industry and exclusive, limited-edition products from the top brands in the market, Trap Culture has you covered. Visit our website to learn more about our events, our blog, and our store. Follow us on social media to stay updated on the latest news and promotions. Join the Trap Culture family and experience the most immersive and engaging social cannabis events in Arizona.
Follow us on social media
